Citation tools
"Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design." Clinical Cancer Research
17.19
(2011):
6298-6303.
Web. 08 Mar. 2021.